Company / R&D Expense
Ensysce Biosciences, Inc. R&D Expense History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$7.2M
FY2025
5-year range
$4.7M / $19.8M
FY2022-FY2025
Trend
-4.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $20M to $7M over the past 2 years.
Based on SEC 10-K filings.
$7M in FY2025 with a 3-year CAGR of +15.5%.
Declined from $20M to $7M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +15.5%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of +15.5%, indicating consistent growth.
- In FY2025, r&d expense decreased 4.9% year-over-year.
Company context
Key Data Points
- Altman Z-Score -1.53 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $7.2M | -4.9% |
| FY2024 | $7.6M | -61.7% |
| FY2023 | $19.8M | +322.9% |
| FY2022 | $4.7M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026